Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A
Kunst, V.A.; Nováková, I.R.; Haanen, C.
Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166
1989
ISSN/ISBN: 0028-2162 PMID: 2501689 Document Number: 329117
Document emailed within 1 workday
Related Documents
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Walker, I.; Poon, M.C. 1992: Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group Lancet 339(8784): 61-62
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Lopaciuk, S.; Ziemski, J.M. 1979: Treatment of patients with hemophilia a having antibodies to factor VIIi Acta Haematologica Polonica 10(2): 115-122
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Allain, J.P.; Steinbuch, M.; Meunier, L.; Muller, J.Y.; Soulier, J.P. 1976: Substitutive treatment of hemopjolia a using a new factor VIIi concentrate La Nouvelle Presse Medicale 5(16): 1047-1050
Vianello, F.; Tison, T.; Tagariello, G.; Zerbinati, P.; Zanon, E.; Scarano, L.; Girolami, A. 1999: Serological markers of autoimmunity in patients with hemophilia A: the role of hepatitis C virus infection, alpha-interferon and factor VIII treatment in skewing the immune system toward autoreactivity Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 10(6): 393-397
Petrovic, M.; Derom, E.; Baele, G. 2000: Cyclosporine treatment of acquired hemophilia due to factor VIIi antibodies Haematologica 85(8): 895-896
Sabin, C.; Pasi, J.; Phillips, A.; Elford, J.; Janossy, G.; Lee, C. 1994: CD4+ counts before and after switching to monoclonal high-purity factor VIIi concentrate in HIV-infected haemophilic patients Thrombosis and Haemostasis 72(2): 214-217
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Iizuka, A.; Kuwashima, M.; Nagao, T. 1982: Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 45(5): 987-992
Canales Albendea, M.A.; Villar Camacho, A.; Chamarro Merino, G.; Magallón Martínez, M. 1998: Ultrapure factor VIIi concentrate with double virus inactivation: study of pharmacokinetics in von Willebrand's disease patients Sangre 43(1): 93-94
Landolfi, R.; de Cristofaro, R.; Lazzareschi, I.; Riccardi, R.; Mariani, G. 2000: Immune tolerance by intermittent factor VIIi boluses in two high responder hemophilia a patients Haematologica 85(10 Suppl): 73-74
Mauser-Bunschoten, E.P.; Damen, M.; Reesink, H.W.; Roosendaal, G.; Chamuleau, R.A.; van den Berg, H.M. 1996: Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C Annals of Internal Medicine 125(4): 297-299